Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
INTEGRIS-PSC featured in an oral late breaker presentationSOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...
GlobalData on MSN16h
Gilead’s Livdelzi shows promise in PBC clinical trial
The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.
Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management
Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which ...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
Becker's ASC3d
8 GI studies changing the industry
From studies on endoscopy to IBD, the gastroenterology industry has seen several major changes over the past year. Here are eight studies to know, according to a Nov. 12 report from Medscape : ...
MedPage Today3d
Primary Biliary Cholangitis Incidence and Prevalence Growing
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
Medpage Today on MSN4d
Managing Primary Biliary Cholangitis Progression and Symptoms
Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...
Intercept loses Ocaliva FDA full approval bid in rare liver disease
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
Monthly Prescribing Reference5d
FDA Denies Full Approval of Obeticholic Acid for Primary Biliary Cholangitis
The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.
US FDA declines full approval for Intercept's liver disease drug
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
KNPR6d
Chronic itch is miserable. Scientists are just scratching the surface
Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments. She ...